Ingredient or product comparison
GHK-Cu vs Minoxidil vs Finasteride: Mechanistic Comparison
Primary Target Collagen XVII synthesis, TGF-β2 inhibition KATP channel opening, VEGF upregulation 5α-reductase type II inhibition GHK-Cu targets follicular structure; minoxidil targets vascularity; finasteride targets androgen conversion Onset of Visible Impro
This source-based comparison does not add ratings or recommend a winner.
- Primary Target
- Collagen XVII synthesis, TGF-β2 inhibition
- KATP channel opening, VEGF upregulation
- 5α-reductase type II inhibition
- GHK-Cu targets follicular structure; minoxidil targets vascularity; finasteride targets androgen conversion
- Onset of Visible Improvement
- 12–16 weeks
- 8–12 weeks
- 16–24 weeks
- GHK-Cu's structural remodeling timeline sits between minoxidil's rapid growth stimulus and finasteride's hormonal lag
- Peak Efficacy Timeline
- 24–36 weeks
- 52–104 weeks
- Finasteride requires longest sustained use for maximum benefit; GHK-Cu reaches plateau at 6–9 months
- Efficacy in Late-Stage AGA (Norwood V+)
- Moderate (12–15% density gain)
- Low (5–10% density gain)
- Low to moderate (10–18% density gain)
- GHK-Cu shows less efficacy drop-off in advanced miniaturization compared to minoxidil
- Systemic Side Effect Profile
- None (peptide not absorbed systemically)
- Rare (pericardial effusion, reflex tachycardia in <1%)
- Common (sexual dysfunction 3–8%, neurosteroid effects)
- GHK-Cu's topical-only activity avoids systemic androgen suppression risks
- Professional Assessment
- Best used as adjunct therapy in patients with fibrotic scalp changes or finasteride non-responders; limited monotherapy evidence
- First-line monotherapy for early-stage AGA; well-established efficacy but requires indefinite use
- First-line systemic therapy; most effective for vertex/crown thinning but requires ongoing monitoring
- GHK-Cu fills a niche for patients seeking non-hormonal options or combination protocols